All In MedTech

Device Trial Radar · NCT07843004

Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 4,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

4,000

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Jun 1, 2027

Study completion Jun 1, 2028

Sponsor

Lead sponsor
Pierre EliasAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Edwards Lifesciences; National Heart, Lung, and Blood Institute (NHLBI)
First posted
Sep 25, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Screening
FDA-regulated device
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Doctors are testing a new tool called EchoNext to see if it can help find heart problems earlier. EchoNext looks at the heart's electrical test, called an ECG, and uses artificial intelligence (AI) to check for signs of structural heart disease (SHD). SHD includes conditions like weak heart pumping, heart valve problems, or extra thickening of the heart muscle. These problems are common but often go undiagnosed until they cause serious issues like heart failure or stroke. The main questions this study will answer are: Can EchoNext alerts help emergency doctors find hidden heart problems sooner? Does this lead to more follow-up heart tests, like an echocardiogram (heart ultrasound)? What this means for patients: If a person has an ECG in the Emergency Department, the EchoNext tool may be used to check their heart. If the tool finds something unusual, their doctor may receive an alert and may then recommend further heart tests or follow-up care. This study will help researchers learn if using EchoNext improves early diagnosis and treatment of heart disease.

Conditions

  • Structural Heart Abnormality
  • Valve Heart Disease
  • Heart Diseases
  • Cardiovascular Diseases

Interventions

  • EHR AlertDevice

    EKG Algorithm to identify structural heart disease

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of new diagnoses of Structural Heart Disease (SHD)Time frame: 180 days post index ED visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center / NewYork-Presbyterian

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.